RD 783/34917 – Clinical Trials UK Skip to content

HELP CLINICAL RESEARCH TODAY

If you are a healthy male aged between 18 and 55, then you may be eligible to participate in a clinical trial investigating a treatment being developed for a range of different diseases associated with fibrosis and inflammation.

Various inconvenience payments ranging from £2905 to £3600.

study information

Simbec-Orion Clinical Pharmacology will soon be running a study to investigate a new drug called RXC007.

RXC007 is being developed for the treatment of a range of different diseases associated with fibrosis and inflammation. RXC007 is specifically being developed to treat a condition called idiopathic pulmonary fibrosis (IPF) but may also be utilised in the treatment of non-alcoholic steatohepatitis (NASH), liver and kidney disease.

Currently, there are limited treatment options available for this condition (IPF) which are considered long term and effective and therefore, there is an unmet need to develop potential new treatments which could be more effective.

 

The main objectives of this study are as follows:

  • To determine the safety and tolerability of RXC007 when it is administered as single and multiple doses at different dose strengths over a period of up to 14 days.
  • To investigate the concentration of RXC007 in the blood, how this changes over a period of time and to evaluate whether there are differences in the concentration between different dose strengths over time and between single or multiple doses.
  • To investigate the effect of food on the concentration of RXC007 in the blood and to investigate if there any effects/interactions between RXC007 and 2 other drugs (rosuvastatin and metformin).

PART C – Group 1
Part C is classed as a drug-drug interaction study. This means that you will be given a drug which has a known effect and a known method of breakdown (metabolism) in the body (rosuvastatin – a drug used to lower cholesterol) and then given the study drug (RXC007) to determine if there is any effect
or interaction between the two drugs in the body and whether administration of RXC007 affects the safety, tolerability and concentration in the blood of rosuvastatin.

If you participate in this group, you will be required to stay at the Simbec-Orion clinical unit for a maximum period of 14 days (13 overnight stays) followed by a post study follow-up visit 14 days after the last dose of RXC007/rosuvastatin (Day 23) and you should therefore ensure that you are able to commit to completing this before agreeing to participate in the study.

If you complete this part of the study, you will receive a maximum inconvenience payment of £3600.

PART C – Group 2
Part C is classed as a drug-drug interaction study. This means that you will be given a drug which has a known effect and a known method of breakdown (metabolism) in the body (metformin – a drug used to manage Type 2 diabetes) and then given the study drug (RXC007) to determine if there is any effect or interaction between the two drugs in the body and whether administration of RXC007 affects the safety, tolerability and concentration in the blood of metformin.

If you participate in this group, you will be required to stay at the Simbec-Orion clinical unit for a maximum period of 11 days (10 overnight stays) followed by a post study follow-up visit 14 days after the last dose of RXC007/metformin (Day 21) and you should therefore ensure that you are able to commit to completing this before agreeing to participate in the study.

If you complete this part of the study, you will receive a maximum inconvenience payment of £2905.

 

study timeline

                                      Group 1- Inconvenience Payment £3600                              Group 2 – Inconvenience Payment  £3600

APPLY NOW

Thank you for your interest in joining our panel of healthy volunteers, please register by completing the below form.

This form does not exist